ALK Gene Mutation

15 registered clinical trials studyying ALK Gene Mutation — 7 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK NCT05266846	Hunan Province Tumor Hospital	Phase 2
Recruiting	A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive NCT06378892	Centro di Riferimento Oncologico - Aviano	Phase 2
Recruiting	Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A- NCT05724004	Karolinska University Hospital	N/A
Unknown	Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes NCT05534854	RenJi Hospital	—
Active Not Recruiting	Real-Time Monitoring of Symptoms in Lung Cancer Patients Receiving Oral Targeted Therapies NCT05370469	University of Virginia	N/A
Active Not Recruiting	Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung NCT05200481	Intergroupe Francophone de Cancerologie Thoracique	Phase 2
Recruiting	Alectinib Pharmacokinetic in Patients With NSCLC NCT05713006	Instituto Nacional de Cancerologia de Mexico	Phase 1 / Phase 2
Terminated	A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NCT04849273	Turning Point Therapeutics, Inc.	Phase 1
Recruiting	Longitudinal Assessment of Genomic Alterations and Clonal Evolution in ALK-positive NSCLC (Galileo Project) NCT06234579	Fondazione Policlinico Universitario Agostino Gemelli IRCCS	—
Recruiting	Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation NCT04322890	Hunan Province Tumor Hospital	Phase 2
Unknown	Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell NCT04708639	Aarhus University Hospital	—
Withdrawn	Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Ca NCT03868423	Sameek Roychowdhury	Phase 2
Completed	Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475 NCT03049618	University of Southern California	Phase 2
Recruiting	Early Rebiopsy to Identify Biomarkers of Tumor Cell Survival Following EGFR, ALK, ROS1 or BRAF TKI Therapy NCT03042221	University of Colorado, Denver	—
Completed	French National Observatory of the Patients With Non-small Cell Lung (NSCLC) and Molecular Testings NCT01700582	Intergroupe Francophone de Cancerologie Thoracique	—